AHS Cancer Control Alberta

πŸ‡¨πŸ‡¦Canada
Ownership
Private
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

A Phase III Study of Re-Irradiation in Recurrent Glioblastoma

First Posted Date
2013-04-12
Last Posted Date
2016-03-16
Lead Sponsor
AHS Cancer Control Alberta
Registration Number
NCT01830101
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Active, not recruiting
Conditions
Neuroendocrine Tumors, NET
First Posted Date
2013-01-09
Last Posted Date
2024-01-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
115
Registration Number
NCT01763554
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)

First Posted Date
2012-12-11
Last Posted Date
2017-11-14
Lead Sponsor
AHS Cancer Control Alberta
Registration Number
NCT01747512

A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients

Phase 2
Recruiting
Conditions
Breast Neoplasms
Interventions
Drug: Epirubicin
First Posted Date
2012-12-04
Last Posted Date
2014-10-02
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
48
Registration Number
NCT01740271
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer

Phase 2
Conditions
Lung Cancer
First Posted Date
2012-06-20
Last Posted Date
2014-09-30
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
144
Registration Number
NCT01624051
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

First Posted Date
2012-04-27
Last Posted Date
2014-10-02
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
175
Registration Number
NCT01586611
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer

First Posted Date
2012-01-23
Last Posted Date
2016-02-25
Lead Sponsor
AHS Cancer Control Alberta
Registration Number
NCT01514955

Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
Drug: ABT-888/Bortezomib
First Posted Date
2011-12-20
Last Posted Date
2017-09-25
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
19
Registration Number
NCT01495351
Locations
πŸ‡¨πŸ‡¦

Tom Baker Cancer Centre, Calgary, Alberta, Canada

Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients

First Posted Date
2011-12-09
Last Posted Date
2017-01-25
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
134
Registration Number
NCT01488968
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

To Compare Safety and the General Imaging Pattern of Cyclotron Produced Technetium vs. Generator Produced Technetium in Patients With Thyroid Cancer

Phase 1
Completed
Conditions
Thyroid Neoplasms
Interventions
Drug: GPERT
Drug: CPERT
First Posted Date
2011-09-20
Last Posted Date
2017-11-14
Lead Sponsor
AHS Cancer Control Alberta
Target Recruit Count
30
Registration Number
NCT01437254
Locations
πŸ‡¨πŸ‡¦

Cross Cancer Institute, Edmonton, Alberta, Canada

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy